Avalo Therapeutics, Inc. ( AVTX) - Key Metrics
AVTX Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.83 | -$0.41 | -$0.41 |
| 2026Q1 | $0 | -$0.98 | -$0.88 | -$0.88 |
| 2025Q4 | $0 | -$0.74 | -$0.77 | -$0.77 |
| 2025Q3 | $0 | -$2.19 | -$1.17 | -$1.17 |
| 2025Q2 | $0 | -$1.92 | -$1.05 | -$1.05 |
AVTX Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -5.57 |
| 2026Q1 | 0% | -3.81 |
| 2025Q4 | 0% | -6.14 |
| 2025Q3 | 0% | -1.45 |
| 2025Q2 | 0% | -0.65 |
AVTX
Price: $19.59
52 week price:
Earnings Per Share: -4.41 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 45800
Market Capitalization: 1.0 billion